This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Finn E. Somnier, MD; Niels Keiding, MS; Olaf B. Paulson, MD

Arch Neurol. 1991;48(7):733-739.

Abstract
• The incidence of myasthenia gravis (MG) was found to be constant in calendar time. The mean annual incidence rate was 4.4 per million population. Age- and sex-specific incidence rates disclosed a bimodal appearance for both sexes, with a peak age at onset located in the early-onset group and another peak for late onset of MG. Early onset of MG appeared 10 years later for male individuals than for female individuals, whereas the peak for late onset of MG was located at the same age for both sexes. It is suggested that the separation between early onset and late onset of MG should be at the age of 50 years for both sexes, rather than at 35 to 40 years as accepted in most studies. The prevalence of MG has increased in time. On January 1, 1988, the point prevalence rate was 77 per million population (female subjects, 96, and male subjects, 57). This reflects an improvement in prognosis despite the fact that life expectancy was found to be significantly lower for MG patients than that of the sex- and age-matched population. The factors causing increased mortality were found to be operative throughout the duration of the disease. Maximum severity of disease was reached within 2 years from onset in 78% of the cases, and more than 50% of all MG-related deaths occurred during the same period. In the course of MG, 70% of all patients experience generalized muscular weakness, and 30% to 40% also suffer from respiratory problems.

Author Affiliations
From the Department of Neurology, State University Hospital (Rigshospitalet), Copenhagen, Denmark (Drs Somnier and Paulson), and Statistical Research Unit, University of Copenhagen (Denmark) (Mr Keiding).

Footnotes
Accepted for publication July 20, 1990.

Reprint requests to Department of Neurology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark (Dr Somnier).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evidence report: The medical treatment of ocular myasthenia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Benatar and Kaminski
Neurology 2007;68:2144-2149.
ABSTRACT | FULL TEXT  

Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001
Owe et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:203-207.
ABSTRACT | FULL TEXT  

Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis
Somnier
Neurology 2005;65:928-930.
ABSTRACT | FULL TEXT  

The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands
Wirtz et al.
Neurology 2004;63:397-398.
FULL TEXT  

A population based epidemiological study on myasthenia gravis in Estonia
Oopik et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:1638-1643.
ABSTRACT | FULL TEXT  

The occurrence of anti-titin antibodies and thymomas: A population survey of MG 1970-1999
Somnier and Engel
Neurology 2002;59:92-98.
ABSTRACT | FULL TEXT  

Epidemiology of seropositive myasthenia gravis in Greece
Poulas et al.
J. Neurol. Neurosurg. Psychiatry 2001;71:352-356.
ABSTRACT | FULL TEXT  

Late-Onset Myasthenia Gravis: A Changing Scene
Aarli
Arch Neurol 1999;56:25-27.
ABSTRACT | FULL TEXT  

Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England
Robertson et al.
J. Neurol. Neurosurg. Psychiatry 1998;65:492-496.
ABSTRACT | FULL TEXT  

Mortality and survival in myasthenia gravis: a Danish population based study
Christensen et al.
J. Neurol. Neurosurg. Psychiatry 1998;64:78-83.
ABSTRACT | FULL TEXT